Welcome to our dedicated page for PRF Technologies Ltd. SEC filings (Ticker: PRFX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PainReform Ltd. (PRFX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. PainReform files Form 6-K current reports that furnish press releases, transaction details, financial statements, and other information under the Securities Exchange Act of 1934. These filings document key developments in both its specialty pharmaceutical programs and its DeepSolar energy analytics activities.
Recent 6-K reports include disclosures about PainReform’s majority investment in LayerBio Inc., the company behind the OcuRing™-K sustained-release ocular platform for cataract surgery, along with unaudited pro forma condensed combined financial information and LayerBio’s audited and unaudited financial statements. Other 6-Ks furnish press releases on topics such as acceptance of DeepSolar into the NVIDIA Connect program, the launch of Smart TDD for solar technical due diligence, and the advancement of DeepSolar’s automated reporting engine and DeepSolar Predict forecasting solution.
Filings also cover financial updates, including unaudited condensed financial statements and operating and financial reviews for interim periods, as well as corporate governance matters such as notices and proxy statements for the Annual General Meeting of Shareholders and changes in board composition. Together, these documents form an official record of PainReform’s clinical, commercial, and corporate progress.
On Stock Titan, investors can review these SEC submissions alongside AI-powered summaries that explain the significance of each report. Real-time updates from EDGAR help users follow new Form 6-K filings as they appear, while structured access to exhibits and financial data supports deeper analysis of PainReform’s pharmaceutical pipeline, LayerBio acquisition, and DeepSolar initiatives.
PRF Technologies reported a major strategic and financial shift for the year ended December 31, 2025. The company cut its net loss to approximately $4.8 million from about $14.6 million in 2024, driven largely by lower clinical trial spending as research and development expenses fell to roughly $1.1 million from $11.7 million. General and administrative expenses were about $3.0 million in both years. As of December 31, 2025, PRF held approximately $4.1 million in cash, cash equivalents, short-term deposits and restricted cash, with positive working capital of about $1.9 million, supported by at-the-market issuances generating around $4.0 million in gross proceeds.
Strategically, PRF strengthened its healthcare platform through a majority investment in LayerBio and advancement of the OcuRing™-K ocular drug-delivery program toward a planned Phase II IND, following preclinical and Phase I data showing a favorable safety profile with no treatment-related serious adverse events. In parallel, the DeepSolar business moved from acquisition to initial commercial deployment, including a pilot with Econergy at a 92 MW Romanian photovoltaic plant that converted into a commercial agreement, a SaaS engagement with Shikun & Binui Energy for the 71 MW Satu Mare site, and a due diligence engagement with EDF Power Solutions Israel, alongside new product launches and its first DeepSolar-related patent application.
PRF Technologies Ltd. files its annual report on Form 20-F describing a very early-stage, loss-making business with substantial doubt about its ability to continue as a going concern. As of December 31, 2025, it held $4.1 million in cash and cash equivalents and had an accumulated deficit of $61.3 million, after three straight years of annual losses of approximately $4.8 million, $14.6 million and $9.3 million. The company has never generated significant revenues, depends on the development and approval of drug candidates such as OcuRing™-K and PRF-110, and is only beginning to commercialize its DeepSolar AI solar analytics business. Management notes it will need substantial additional funding through equity, debt or strategic transactions and that failure to raise capital could force it to scale back or cease operations, which could severely impair shareholder value. The report also details multiple reverse share splits through February 2026 and extensive risk factors across drug development, regulation, AI and solar markets, and intellectual property.
PRF Technologies Ltd. filed a Form 3 for Chief Operating Officer Aviel Sigal, detailing existing employee stock option holdings over a total of 3,759 underlying ordinary shares. These options were granted under the 2019 PainReform Option Plan and are subject to Israeli Section 102 trustee arrangements.
Several grants are already fully vested, with grant dates on September 5, 2019, November 23, 2022, and October 10, 2024. A grant covering 3,000 underlying shares dated February 20, 2025 has 750 options vested at appointment, with the remaining 2,250 scheduled to vest in equal quarterly installments beginning on May 20, 2026, until fully vested on the three-year anniversary of the grant date, contingent on continued service.
PRF Technologies Ltd. director Ellen S. Baron filed an initial ownership report showing she holds employee stock options over 50 Ordinary Shares at a 5,400.0000 exercise price, expiring on February 23, 2031, and 183 options at a 30.0000 exercise price, expiring on July 18, 2034.
The 2021 grant is fully vested. For the 2024 grant, 160 options were vested at appointment, and 23 will vest in two quarterly installments on April 18, 2026 and July 18, 2026, subject to her continued service.
PRF Technologies Ltd. interim CEO Cohen-Arazi Efraim filed an initial ownership report listing direct holdings of several employee stock option grants over the company’s Ordinary Shares. These options give the right to buy shares at exercise prices ranging from 15.7500 to 5400.0000 per share, with expirations between 2031 and 2035.
Footnotes explain that the options were granted under the 2019 PainReform Option Plan and, to qualify for Israeli tax benefits under Section 102, must be registered in the name of a trustee. They also outline vesting schedules, with some grants already fully vested and others vesting in quarterly installments through 2028, contingent on continued service.
PRF Technologies Ltd. executive chairman Ehud Geller filed an initial Form 3 showing his derivative holdings in employee stock options over ordinary shares. The filing lists several option grants under the 2019 PainReform Option Plan, fully vested on their respective grant dates, with exercise prices ranging from 0.0500 to 5400.0000 and expirations between 2031 and 2035. These entries reflect existing option positions rather than new purchases or sales.
PRF Technologies Ltd. filed an initial ownership report for Chief Financial Officer Broder Eyal, showing existing stock option awards rather than new share purchases or sales. He holds options over 180 ordinary shares at an exercise price of $30.0000 expiring on October 10, 2034, fully vested on the grant date. He also holds options over 2,000 ordinary shares at an exercise price of $15.7500 expiring on February 20, 2035, with 500 options vested at appointment and the remaining 1,500 vesting in equal quarterly installments beginning on May 20, 2026, subject to his continued service.
PRF Technologies Ltd. director Augustine Lawlor reported his initial holdings of stock options linked to the company’s ordinary shares. These are compensation awards rather than open-market trades.
One option covers 50 ordinary shares at an exercise price of 5,400 per share, expiring on February 23, 2031, and is fully vested from a February 23, 2021 grant under the 2019 PainReform Option Plan. A second option covers 183 ordinary shares at an exercise price of 30 per share, expiring on July 18, 2034. Of this grant, 160 options were vested on the appointment date, and the remaining 23 are scheduled to vest in two quarterly installments on April 18, 2026 and July 18, 2026, contingent on continued service.
PRF Technologies Ltd. director Shavit Asaf reported holding employee stock options linked to 3,000 Ordinary Shares. These options have an exercise price of 5.55 per share and expire on November 24, 2035.
The options were granted under the 2019 PainReform Option Plan and will vest in equal quarterly installments starting three months after the November 24, 2025 grant date, becoming fully vested three years after that date if his service continues. For Israeli tax benefits under Section 102 of the Israeli Tax Ordinance, the securities must be registered in the name of a trustee.
PRF Technologies Ltd. reported a new commercial collaboration agreement with Blade Ranger Ltd. to help expand deployments of its DeepSolar AI-driven solar analytics platform across utility-scale solar portfolios, targeting engagements of at least 150 megawatts each.
Under the agreement, Blade Ranger will identify and introduce potential large solar customers. As consideration, Blade Ranger may receive warrants to purchase 100,000 restricted ordinary shares for each of up to three prospects that sign binding DeepSolar agreements meeting the minimum 150 megawatt scope, for a maximum of 300,000 shares. The warrants carry a $0.01 exercise price per share and a 12‑month term from issuance.
PRF has also agreed, upon Blade Ranger’s written request, to register the warrant shares for resale, with Blade Ranger reimbursing half of the related registration costs. The filing highlights PRF’s strategy to grow DeepSolar alongside its pharmaceutical programs by partnering with a specialist in large‑scale renewable energy infrastructure.